Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V-Reference-Cited by-同舟云学术

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V

Published:2018-08-20 Issue:2 Volume:183 Page:257-266
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Yada Koji¹,Nogami Keiji¹^ORCID,Shinozawa Keiko²,Kitazawa Takehisa³,Hattori Kunihiro³,Amano Kagehiro²⁴,Fukutake Katsuyuki²⁴,Shima Midori¹

Affiliation:

1. Department of Paediatrics; Nara Medical University; Kashihara Japan

2. Department of Molecular Genetics of Coagulation Disorders; Tokyo Medical University; Tokyo Japan

3. Research Division; Chugai Pharmaceutical Co., Ltd.; Kamakura Japan

4. Laboratory Medicine; Tokyo Medical University; Tokyo Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15525/fullpdf

Reference38 articles.

1. Mutation in blood coagulation factor V associated with resistance to activated protein C;Bertina;Nature,1994

2. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?;Bos;Journal of Thrombosis and Haemostasis,2005

3. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations;Castoldi;Blood,2004

4. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders;Dahlbäck;International Journal of Laboratory Hematology,2016

5. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C;Dahlbäck;Proceedings of the National Academy of Sciences of the United States of America,1993

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro;Thrombosis Research;2024-05

2. Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates;Research and Practice in Thrombosis and Haemostasis;2024-05

3. NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V;Research and Practice in Thrombosis and Haemostasis;2024-01

4. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma;International Journal of Hematology;2023-12-19

5. Influence of emicizumab on protein C-mediated clotting regulation;Bleeding, Thrombosis, and Vascular Biology;2023-10-25